Toll-like receptor 2/6 stimulation promotes angiogenesis via GM-CSF as a potential strategy for immune defense and tissue regeneration

Blood

Volumn 115, Issue 12, 2010, Pages 2543-2552

  Grote, Karsten ^a   Schuett, Harald ^a   Salguero, Gustavo ^a   Grothusen, Christina ^a   Jagielska, Joanna ^a   Drexler, Helmut ^a   Mühlradt, Peter F ^b   Schieffer, Bernhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b BioTec Gründerzentrum Braunschweig   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD45 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; MATRIGEL; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; LEUKOCYTE MIGRATION; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE REGENERATION; UPREGULATION;

EID: 77950554962     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-05-224402     Document Type: Article

References (39)

1. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388(6640):394-397. (Pubitemid 27334820)
2. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376.
3. Brikos C, O'Neill LA. Signalling of toll-like receptors. Handb Exp Pharmacol. 2008;183:21-50.
4. Kaisho T, Akira S. Regulation of dendritic cell function through toll-like receptors. Curr Mol Med. 2003;3(8):759-771. (Pubitemid 37536880)
5. Satoh M, Ishikawa Y, Minami Y, Takahashi Y, Nakamura M. Role of Toll like receptor signaling pathway in ischemic coronary artery disease. Front Biosci. 2008;13:6708-6715.
6. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology. 2008;48(1):322-335. (Pubitemid 351975556)
7. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006;6(11):823-835. (Pubitemid 44631651)
8. Obhrai J, Goldstein DR. The role of toll-like receptors in solid organ transplantation. Transplantation. 2006;81(4):497-502. (Pubitemid 43315951)
9. Deiters U, Barsig J, Tawil B, Muhlradt PF. The macrophage-activating lipopeptide-2 accelerates wound healing in diabetic mice. Exp Dermatol. 2004;13(12):731-739. (Pubitemid 39625219)
10. Macedo L, Pinhal-Enfield G, Alshits V, et al. Wound healing is impaired in MyD88-deficient mice: a role for MyD88 in the regulation of wound healing by adenosine A2A receptors. Am J Pathol. 2007;171(6):1774-1788.
11. Seki E, Tsutsui H, Iimuro Y, et al. Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration. Hepatology. 2005;41(3):443-450. (Pubitemid 40289490)
12. Muhlradt PF, Kiess M, Meyer H, Sussmuth R, Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med. 1997;185(11):1951-1958. (Pubitemid 27247081)
13. Takeuchi O, Kaufmann A, Grote K, et al. Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88-dependent signaling pathway. J Immunol. 2000;164(2):554-557. (Pubitemid 30043671)
14. Takeuchi O, Kawai T, Muhlradt PF, et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol. 2001;13(7):933-940. (Pubitemid 32685205)
15. Rharbaoui F, Drabner B, Borsutzky S, et al. The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur J Immunol. 2002; 32(10):2857-2865. (Pubitemid 35238178)
16. Deiters U, Gumenscheimer M, Galanos C, Muhlradt PF. Toll-like receptor 2- and 6-mediated stimulation by macrophage-activating lipopeptide 2 induces lipopolysaccharide (LPS) cross tolerance in mice, which results in protection from tumor necrosis factor alpha but in only partial protection from lethal LPS doses. Infect Immun. 2003;71(8):4456-4462. (Pubitemid 36919912)
17. Pandya NM, Dhalla NS, Santani DD. Angiogenesis: a new target for future therapy. Vascul Pharmacol. 2006;44(5):265-274.
18. Frantz S, Vincent KA, Feron O, Kelly RA. Innate immunity and angiogenesis. Circ Res. 2005; 96(1):15-26.
19. National Center for Biotechnology Information. GenBank. http://www.ncbi.nlm.nih.gov/Genbank. Accessed April 30, 2004.
20. Quandt K, Frech K, Karas H, Wingender E, Werner T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res. 1995;23(23):4878-4884. (Pubitemid 3008389)
21. Grote K, Salguero G, Ballmaier M, Dangers M, Drexler H, Schieffer B. The angiogenic factor CCN1 promotes adhesion and migration of circulating CD34+ progenitor cells: potential role in angiogenesis and endothelial regeneration. Blood. 2007;110(3):877-885. (Pubitemid 47267424)
22. Oda K, Kitano H. A comprehensive map of the toll-like receptor signaling network. Mol Syst Biol. 2006;2:2006.0015.
23. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219(4587): 983-985.
24. Esch F, Baird A, Ling N, et al. Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proc Natl Acad Sci U S A. 1985;82(19):6507-6511.
25. Bussolino F, Ziche M, Wang JM, et al. In vitro and in vivo activation of endothelial cells by colony-stimulating factors. J Clin Invest. 1991;87(3):986-995.
26. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79(2):315-328. (Pubitemid 24324921)
27. Hamilton JA, Anderson GP. GM-CSF biology. Growth Factors. 2004;22(4):225-231.
28. Muhlradt PF, Kiess M, Meyer H, Sussmuth R, Jung G. Structure and specific activity of macrophage-stimulating lipopeptides from Mycoplasma hyorhinis. Infect Immun. 1998;66(10):4804-4810.
29. Kurokawa K, Lee H, Roh KB, et al. The triacylated ATP binding cluster transporter substrate-binding lipoprotein of Staphylococcus aureus functions as a native ligand for the toll-like receptor 2. J Biol Chem. 2009;284(13):8406- 8411.
30. McDonald DM. Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med. 2001;164(10):S39-S45.
31. McCurdy JD, Olynych TJ, Maher LH, Marshall JS. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J Immunol. 2003;170(4):1625-1629.
32. Zahringer U, Lindner B, Inamura S, Heine H, Alexander C. TLR2: promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology. 2008; 213(3):205-224.
33. Pollet I, Opina CJ, Zimmerman C, Leong KG, Wong F, Karsan A. Bacterial lipopolysaccharide directly induces angiogenesis through TRAF6-mediated activation of NF-kappaB and c-Jun N-terminal kinase. Blood. 2003;102(5):1740- 1742. (Pubitemid 37022568)
34. Niebuhr M, Muhlradt PF, Wittmann M, Kapp A, Werfel T. Intracutaneous injection of the macrophage-activating lipopeptide-2 (MALP-2) which accelerates wound healing in mice: a phase I trial in 12 patients. Exp Dermatol. 2008;17(12):1052-1056.
35. Shingu K, Kruschinski C, Luhrmann A, et al. Intratracheal macrophage-activating lipopeptide-2 reduces metastasis in the rat lung. Am J Respir Cell Mol Biol. 2003;28(3):316-321. (Pubitemid 36238008)
36. Schneider C, Schmidt T, Ziske C, et al. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut. 2004; 53(3):355-361. (Pubitemid 38241329)
37. Schmidt J, Welsch T, Jager D, Muhlradt PF, Buchler MW, Marten A. Intratumoural injection of the toll-like receptor-2/6 agonist "macrophage-activating lipopeptide-2" in patients with pancreatic carcinoma: a phase I/II trial. Br J Cancer. 2007;97(5):598-604.
38. Kovacic JC, Muller DW, Graham RM. Actions and therapeutic potential of G-CSF and GM-CSF in cardiovascular disease. J Mol Cell Cardiol. 2007; 42(1):19-33. (Pubitemid 44958629)
39. Sepulveda P, Martinez-Leon J, Garcia-Verdugo JM. Neoangiogenesis with endothelial precursors for the treatment of ischemia. Transplant Proc. 2007;39(7):2089-2094. (Pubitemid 47418187)